{"id":"bebt-209-capsules","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL3649169","moleculeType":"Small molecule","molecularWeight":"417.52"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the SGLT2 receptor, BEBT-209 capsules reduce glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. The drug's effects on blood glucose levels may also have secondary benefits for patients with cardiovascular disease.","oneSentence":"BEBT-209 capsules are a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:18.908Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Cardiovascular disease"}]},"trialDetails":[{"nctId":"NCT06998108","phase":"PHASE3","title":"Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy","status":"RECRUITING","sponsor":"BeBetter Med Inc","startDate":"2022-06-09","conditions":"HR+/HER2- Locally Advanced, Metastatic Breast Cancer","enrollment":330},{"nctId":"NCT06685796","phase":"PHASE2","title":"A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"BeBetter Med Inc","startDate":"2023-04-12","conditions":"Advanced Triple-Negative Breast Cancer","enrollment":120},{"nctId":"NCT06047184","phase":"PHASE1","title":"Phase I Study of BEBT-209 in Women With Advanced Breast Cancer","status":"UNKNOWN","sponsor":"BeBetter Med Inc","startDate":"2019-07-15","conditions":"Advanced Breast Cancer","enrollment":106}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["KCBT-0191","BEBT-209"],"phase":"phase_3","status":"active","brandName":"BEBT-209 capsules","genericName":"BEBT-209 capsules","companyName":"BeBetter Med Inc","companyId":"bebetter-med-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BEBT-209 capsules are a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes, Cardiovascular disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}